In that study, 5674 patients with type 2 diabetes and CKD (those with urinary albumin of 30 to <300 mg/gCr, an eGFR of 25 to <60 mL/min/1.73 m2, and diabetic retinopathy or urinary albumin of 300 to 5000 mg/gCr and an eGFR of 25 to <75 mL/min/1.73 m2) were randomized to receive finerenone or a placebo. This evidence concerns the gene ALB and chronic kidney disease.